Top news of the week from Specialty Pharmacy Times.
5. Looming Biosimilars May Impact Top Selling Rheumatoid Arthritis Drug
Spending for adalimumab has tripled from 2012 from $4.5 billion. Read more.
4. Alternative Splicing Changes May Represent Independent Oncogenic Processes
New findings suggest alterations in this process may trigger cancer progression. Read more. 3.
Merck Nixes Development of Two Hepatitis C Drugs Due to Overcrowded Market
The pharma giant will now focus on its PD-1 cancer immunotherapy Keytruda. Read more.
2. Specialty Pharmacy Accreditation: To Be or Not to Be, That is the Question
Becoming an accredited specialty pharmacy requires a large time investment and a significant commitment to properly record and report specific data. Read more.
1. Americans Want to Interact with Pharmacists Online
Nearly 80% of Americans said they would follow their pharmacist on social media. Read more.